Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 Rα), FOXP3 and IL-6 expressions as genes affecting immune homeostasis.
COVID-19
Celiac disease
Gene expression
Interleukin-6
Regulatory
SARS-CoV-2
T-Lymphocytes
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
11 Dec 2021
11 Dec 2021
Historique:
received:
14
08
2021
accepted:
07
12
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is defined as an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 and celiac disease (CD) is one of the autoimmune multiorgan diseases, which can be accompanied by an increased risk of viral infections. CD patients, especially untreated subjects, may be at greater risk of infections such as viral illnesses. Interleukin (IL)-6, CD4, CD25, and FOXP3 are known as genes affecting immune homeostasis and relate to the inflammation state. This study aimed to compare the expression levels of aforementioned genes in peripheral blood samples of CD and severe COVID-19 patients. Sixty newly diagnosed CD patients with median age (mean ± SD) of 35.40 ± 24.12 years; thirty confirmed severe COVID-19 patients with median age (mean ± SD) of 59.67 ± 17.22, and 60 healthy subjects with median age (mean ± SD) of 35.6 ± 13.02 years; were recruited from March to September 2020. Fresh whole blood samples were collected, total RNA was obtained and cDNA synthesis was carried out. RNA expression levels of IL-6, CD4, CD25, and FOXP3 genes were assessed using real-time quantitative RT-PCR according to the 2 While increased expression of CD4, CD25, and FOXP3 was observed in CD patients compared to the control group (p = 0.02, p = 0.03, and p < 0.0001 respectively) and COVID-19 patients group (p < 0.0001 for all of them), their expression levels in COVID-19 patients decreased compared to controls (p < 0.0001, p = 0.01, p = 0.007, respectively). Increased IL-6 expression was observed in both groups of patients compared to controls (p < 0.0001 for both of them). Although untreated CD patients may be at greater risk of developing into severe COVID-19 if they are infected by SARS-CoV-2 virus (due to their high expression of IL-6), increased expression of anti-inflammatory markers in these patients may be beneficial for them with the ability of reducing the severity of COVID-19 disease, which needs to be proven in future studies involving celiac patients infected with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) is defined as an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 and celiac disease (CD) is one of the autoimmune multiorgan diseases, which can be accompanied by an increased risk of viral infections. CD patients, especially untreated subjects, may be at greater risk of infections such as viral illnesses. Interleukin (IL)-6, CD4, CD25, and FOXP3 are known as genes affecting immune homeostasis and relate to the inflammation state. This study aimed to compare the expression levels of aforementioned genes in peripheral blood samples of CD and severe COVID-19 patients.
METHODS
METHODS
Sixty newly diagnosed CD patients with median age (mean ± SD) of 35.40 ± 24.12 years; thirty confirmed severe COVID-19 patients with median age (mean ± SD) of 59.67 ± 17.22, and 60 healthy subjects with median age (mean ± SD) of 35.6 ± 13.02 years; were recruited from March to September 2020. Fresh whole blood samples were collected, total RNA was obtained and cDNA synthesis was carried out. RNA expression levels of IL-6, CD4, CD25, and FOXP3 genes were assessed using real-time quantitative RT-PCR according to the 2
RESULTS
RESULTS
While increased expression of CD4, CD25, and FOXP3 was observed in CD patients compared to the control group (p = 0.02, p = 0.03, and p < 0.0001 respectively) and COVID-19 patients group (p < 0.0001 for all of them), their expression levels in COVID-19 patients decreased compared to controls (p < 0.0001, p = 0.01, p = 0.007, respectively). Increased IL-6 expression was observed in both groups of patients compared to controls (p < 0.0001 for both of them).
CONCLUSIONS
CONCLUSIONS
Although untreated CD patients may be at greater risk of developing into severe COVID-19 if they are infected by SARS-CoV-2 virus (due to their high expression of IL-6), increased expression of anti-inflammatory markers in these patients may be beneficial for them with the ability of reducing the severity of COVID-19 disease, which needs to be proven in future studies involving celiac patients infected with COVID-19.
Identifiants
pubmed: 34895167
doi: 10.1186/s12876-021-02056-1
pii: 10.1186/s12876-021-02056-1
pmc: PMC8665626
doi:
Substances chimiques
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Interleukin-2
0
Interleukin-6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
462Informations de copyright
© 2021. The Author(s).
Références
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Trends Immunol. 2012 Nov;33(11):571-7
pubmed: 22883707
Front Pharmacol. 2015 Sep 02;6:184
pubmed: 26388774
Mol Med Rep. 2018 Mar;17(3):3647-3657
pubmed: 29286140
Iran Biomed J. 2020 Jan 18;24(3):140-7
pubmed: 31952431
J Infect. 2020 Sep;81(3):452-482
pubmed: 32526326
J Cell Physiol. 2021 Apr;236(4):2829-2839
pubmed: 32926425
Immunology. 2013 Jan;138(1):23-33
pubmed: 22913724
Front Immunol. 2017 May 26;8:605
pubmed: 28603524
Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S117-S122
pubmed: 32099611
Cancer Immunol Res. 2016 Sep 2;4(9):721-5
pubmed: 27590281
Front Immunol. 2012 Jul 31;3:211
pubmed: 23060872
Lancet Rheumatol. 2021 Jan;3(1):e6-e8
pubmed: 33521668
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Cytokine Growth Factor Rev. 2020 Jun;53:13-24
pubmed: 32475759
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Eur Respir J. 2020 Sep 3;56(3):
pubmed: 32616599
BMC Gastroenterol. 2012 Jul 31;12:97
pubmed: 22849659
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
Front Nutr. 2020 Feb 07;7:6
pubmed: 32118025
Int J Biol Sci. 2021 Apr 10;17(6):1507-1520
pubmed: 33907514
Immunol Cell Biol. 1990 Jun;68 ( Pt 3):155-60
pubmed: 2228030
Life Sci. 2020 Sep 15;257:118097
pubmed: 32679148
Curr Res Transl Med. 2020 Aug;68(3):125-130
pubmed: 32414632
Gastroenterol Hepatol Bed Bench. 2020 Fall;13(4):388-392
pubmed: 33244382
Science. 2001 May 11;292(5519):1112-5
pubmed: 11352067
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Ann Lab Med. 2021 Nov 1;41(6):540-548
pubmed: 34108281
BMC Gastroenterol. 2020 Nov 19;20(1):387
pubmed: 33213379
Clin Immunol. 2020 Jun;215:108448
pubmed: 32353634
Clin Exp Immunol. 2008 Jun;152(3):498-507
pubmed: 18435801
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13073-8
pubmed: 23878218
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G161-G170
pubmed: 31188640
Autoimmun Rev. 2020 Oct;19(10):102639
pubmed: 32801048
Lab Med. 2021 Sep 1;52(5):493-498
pubmed: 33928380
Biomed Pharmacother. 2020 Nov;131:110698
pubmed: 32920514
J Immunol. 2017 Apr 15;198(8):3005-3014
pubmed: 28373482
Hum Immunol. 2009 Jun;70(6):430-5
pubmed: 19364517
Front Microbiol. 2019 May 10;10:1057
pubmed: 31134045
Virology. 2009 Mar 15;385(2):358-67
pubmed: 19141357
Acta Gastroenterol Belg. 2020 Oct-Dec;83(4):517-525
pubmed: 33321006
Prz Gastroenterol. 2018;13(4):293-298
pubmed: 30581503
Scand J Gastroenterol. 2009;44(4):422-30
pubmed: 19096978
Immunity. 2008 Apr;28(4):454-67
pubmed: 18400188
Adv Pediatr. 2008;55:349-65
pubmed: 19048738
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Clin Transl Immunology. 2016 Nov 02;5(11):e112
pubmed: 27990287
Cell Host Microbe. 2020 Jun 10;27(6):879-882.e2
pubmed: 32359396
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566